Glaxo says cervical cancer vaccine works for longer

LONDON (Reuters) - GlaxoSmithKline said on Wednesday new data showed its Cervarix vaccine generated sustained, high levels of neutralizing antibodies against the two most common cervical cancer-causing virus types for 6.4 years.

Continue to Glaxo says cervical cancer vaccine works for longer on Reuters Health eLine.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz